A Randomised, Double-blind, Placebo-controlled, Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) Administered by Subcutaneous (SC) Injection for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Occurence of adverse events and antibody formation to NESP
throughout the study
Yes
MD
Study Director
Amgen
Austria: Bundesamt für Sicherheit im Gesundheitswesen
980291
NCT00540384
July 1999
June 2002
Name | Location |
---|